Subsidiary of Xizang Weixinkang Pharmaceutical (603676.SH) receives registration certificate for injection of Isavuconazole sulfate drugs.
Weixinkang (603676.SH) announced that its wholly-owned subsidiary, Inner Mongolia Beiyi Pharmaceutical Co., Ltd. (referred to as "Beiyi Pharmaceutical"), recently received the Drug Registration Certificate for injection of esophagandazole sulfate issued by the National Medical Products Administration. Esophagandazole sulfate for injection is suitable for the treatment of invasive aspergillosis and invasive mucormycosis in adult patients.
Xizang Weixinkang Pharmaceutical (603676.SH) announced that its wholly-owned subsidiary Inner Mongolia Baiyi Pharmaceutical Co., Ltd. (referred to as "Baiyi Pharmaceutical") recently received the Drug Registration Certificate for injection of Isavuconazole sulfate issued by the National Medical Products Administration. Injection of Isavuconazole sulfate is used for the treatment of invasive aspergillosis and invasive mucormycosis in adult patients.
Related Articles
.png)
US Stock Market Move | Q4 performance and revenue outlook exceed expectations, Marvell Technology, Inc. (MRVL.US) is up over 16.8%.
US Stock Market Move | BlackRock, Inc. (BLK.US) falls more than 5%, $25 million private lending valuation drops to zero
As Paramount Sky (PSKY.US) acquisition transaction progresses, Warner Bros. Discovery (WBD.US) CEO and other executives collectively sold over 200 million dollars worth of company stocks.
US Stock Market Move | Q4 performance and revenue outlook exceed expectations, Marvell Technology, Inc. (MRVL.US) is up over 16.8%.
US Stock Market Move | BlackRock, Inc. (BLK.US) falls more than 5%, $25 million private lending valuation drops to zero
As Paramount Sky (PSKY.US) acquisition transaction progresses, Warner Bros. Discovery (WBD.US) CEO and other executives collectively sold over 200 million dollars worth of company stocks.
RECOMMEND
